Crossmark

Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy

Crossref DOI link: https://doi.org/10.1136/jitc-2022-004717

Published Online: 2022-09-22

Published Print: 2022-09

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Krieg, Carsten

Weber, Lukas M

Fosso, Bruno

Marzano, Marinella https://orcid.org/0000-0002-9996-8817
Hardiman, Gary

Olcina, Monica M

Domingo, Enric https://orcid.org/0000-0003-4390-8767
El Aidy, Sahar

Mallah, Khalil

Robinson, Mark D

Guglietta, Silvia https://orcid.org/0000-0001-9998-5716
Funding

Funding for this research was provided by:

National Institute of General Medical Sciences (P20GM130457)

Fondazione Umberto Veronesi (N/A)

American Cancer Society (N/A)

Medical Research Council (MC_UU_00001/10)

Associazione Italiana Ricerca sul Cancro (N/A)

National Cancer Institute (R01CA258882-01A1)

Cancer Research UK (MR/M016587/1)
License Information

License valid from 2022-09-22